Human T-lymphotropic virus: Difference between revisions

From Citizendium
Jump to navigation Jump to search
imported>Sai Kappagantula
mNo edit summary
 
(13 intermediate revisions by 3 users not shown)
Line 1: Line 1:
{{Subpages}}
{{Subpages}}
{{EZarticle-closed-auto‎}}
{{Taxobox | color=violet
| name = Human T-lymphotropic virus
| image = HTLV-1_1.jpg
| virus_group = Group VI (ssRNA-RT)
| familia = Retroviridae
| genus = Deltaretrovirus
| sero_complex = Human T-lymphotropic virus}}


==Classification==
'''Human T-lymphotropic virus''' was first discovered in Japan in 1977 as the first human [[retrovirus]] to be identified as such. It is thought to be the disease-causing agent in several ailments. [[Paraparesis]] is one disease thought to be caused by the virus where an individual's lower extremities are impaired. The virus is also thought to be an [[oncovirus]], a [[cancer]] causing viral agent. [[Leukemia]], a cancer of [[bone marrow]] or [[blood cells]], has been linked to T-lymphotropic virus.
 
===Higher order taxa===
 
Viral Group: Group VI (ssRNA-RT)
 
Family: Retroviridae
 
Genus: Deltaretrovirus
 
Species: Human T-lymphotropic virus
 
===Species===
 
''Deltaretrovirus Human T-lymphotropic virus'' [[Image:HTLV-1_1.jpg]]
 
==Description and significance==
Describe the appearance, habitat, etc. of the organism, and why it is important enough to have its genome sequenced. Describe how and where it was isolated. Include a picture or two (with sources) if you can find them.
 
Human T-lymphotropic virus was first discovered in Japan in 1977 as the first human retrovirus to be identified as such. It is thought to be the disease causing agent in several ailments. Paraparesis is one disease thought to be caused by the virus where an individual's lower extremities are impaired. The virus is also thought to be an oncovirus, a cancer causing viral agent. Leukemia, a cancer of bone marrow or blood cells, has been linked to T-lymphotropic virus.


==Genome structure==
==Genome structure==
 
The virus' genome consists of a single strand of RNA and uses [[reverse transcription]] to form DNA from an RNA template. Among [[retroviruses]] HTLV has a unique genome that leads to its unusual pathogenesis. It shares with other viruses the gag-pol-env motif with flanking LTR (long terminal repeat) sequences. It, however, includes a fourth sequence which acts in an ORF([[open reading frame]]), and leads to products that are most likely pathogenic: Tax, Rex, p12, p13, and p30.
Describe the size and content of the genome.  How many chromosomes?  Circular or linear?  Other interesting features?  What is known about its sequence?
Does it have any plasmids?  Are they important to the organism's lifestyle?
 
The virus' genome consists of a single strand of RNA and uses reverse transcription to form DNA from an RNA template. HTLV has a unique genome among retroviruses that highlights its unusual pathogenesis. It has the same gag-pol-env motif, with flanking long terminal repeat sequences (LTR), as all retroviruses. However, it includes a fourth sequence (xP), which participates in open-reading-frame transcription and leads to what are likely pathogenic products: Tax, Rex, p12, p13, and p30.


==Cell structure and metabolism==
==Cell structure and metabolism==


Describe any interesting features and/or cell structures; how it gains energy; what important molecules it produces.
HTLV is an [[enveloped virus]]. A core contains the genetic material as well as reverse transcribing proteins that facilitate transcription from RNA to DNA. This core is encased in a protein shell called a [[capsid]]. The outer most portion of the virus is the envelope - a [[phospholipid bilayer]] derived from the host cell that helps the virus invade a host cell. Between the envelope and the capsid is a collection of proteins called the [[tegument]].
 
HTLV is an enveloped virus. A core contains the genetic material as well as reverse transcribing proteins that facilitate transcription from RNA to DNA. This core is encased in a protein shell called a capsid. The outer most portion of the virus is the envelope - a phospholipid bilayer derived from the host cell that helps the virus invade a host cell. Between the envelope and the capsid is a collection of proteins called the tegument.


==Ecology==
==Ecology==
Describe any interactions with other organisms (included eukaryotes), contributions to the environment, effect on environment, etc.
HTLV interacts primarily with human hosts. Close relatives of the virus, however, do exist and invade other animal hosts.
HTLV interacts primarily with human hosts. Close relatives of the virus, however, do exist and invade other animal hosts.


==Pathology==
==Pathology==


How does this organism cause disease?  Human, animal, plant hosts?  Virulence factors, as well as patient symptoms.
The virus, once in the host, can cause a variety of disease. These diseases include HTLV-1 associated [[myelopathy]], [[opportunistic infections]] from other microbes due to a debilitated immune system, and cancer. In respect to debilitating the immune system, a unique feedback process involving Tax and Rex, an early and rapid replication of the virus is attained. This is followed by a sudden halt to viral replication. The quick replication and abrupt stop  sequence allows for the virus to avoid host defenses. This places HTLV in the unique category of [[delta retroviruses]], whose only other members are a few nonhuman viruses: BLV, STLV (simian T-cell leukemia virus), and PTLV (primate T-cell leukemia virus).
 
The virus, once in the host, can cause a variety of disease. These diseases include HTLV-1 associated myelopathy, opportunistic infections from other microbes due to a debilitated immune system, and cancer. Through a unique feedback mechanism involving Tax and Rex that early, rapid replication of the virus is achieved, followed by abrupt inhibition of viral replication. This replication surge and termination sequence allow for dissemination in acute infection, followed by a quiescent phase in which HTLV evades host immune defenses. This places HTLV in the unique category of delta retroviruses, whose only other members are a few nonhuman viruses: BLV, STLV (simian T-cell leukemia virus), and PTLV (primate T-cell leukemia virus).


==Application to Biotechnology==
==Application to Biotechnology==
Does this organism produce any useful compounds or enzymes?  What are they and how are they used?


==Current Research==
==Current Research==
'''Human T-lymphotropic virus type I infection.'''
1. Project by The Nyborg Lab of Colorado State University is underway to explore the transciptional regulation of T-cells infected with HTLV. The goal is to study the interactions between the viral proteins, such as the Tax protein, and cellular machinery in vivo and in vitro. ''http://www.nyborglab.com/research.htm''
Human T-cell lymphotropic virus type I (HTLV-I) is the first human retrovirus to be associated with malignant disease--namely, adult T-cell leukaemia/lymphoma. HTLV-I has also been associated with several non-malignant conditions, notably the chronic neurodegenerative disorder, HTLV-I associated myelopathy (also known as tropical spastic paraparesis), infective dermatitis of children and uveitis. More recent evidence points to disease associations not previously linked to HTLV-I. Thus, the disease spectrum of HTLV-I is not fully known. HTLV-I has a worldwide distribution with major endemic foci in the Caribbean and southern Japan. The public health importance is confirmed by the major routes of transmission, which are mother-to-child, blood transfusion, and sexual activity. Unfortunately, no vaccine is available yet and there is no proven treatment for advanced HTLV-I disease. ''http://www.ncbi.nlm.nih.gov/pubmed/10371587''




'''Treatment of adult T-cell leukemia/lymphoma: past, present, and future.'''
2. Study being conducted at Fukuoka University is exploring alternatives to treating Adult T-Cell Leukemia/Lymphoma. Current usage of chemotherapy have insufficient results, but application of stem cell technology has yielded a possible new approach to treating the disease. ''http://www.ncbi.nlm.nih.gov/pubmed/18081707?ordinalpos=6&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum''
Adult T-cell leukemia/lymphoma (ATLL) is a peripheral T-cell malignancy caused by human T-cell lymphotrophic virus type I. Clinical manifestations of ATLL range from smoldering to chronic, lymphoma and acute. Patients with acute and lymphoma type ATLL require therapeutic intervention. Conventional chemotherapeutic regimens used against other malignant lymphoma have been administered to ATLL patients, but the therapeutic outcomes of acute and lymphoma type ATLL remain very poor. Promising results of allogeneic stem cell transplantation (SCT) for ATLL patients have recently been reported and the treatment outcome might be improved for some ATLL patients. Besides conventional chemotherapy and SCT, interferon, zidovudine, arsenic trioxide, targeted therapy against surface molecule on ATLL cells, retinoid derivatives, and bortezomib have been administered to ATLL patients in pilot or phase I/II studies. Further studies are required to confirm the clinical benefits of these novel therapeutics. This article reviews the current status and future directions of ATLL treatment. ''http://www.ncbi.nlm.nih.gov/pubmed/18081707?ordinalpos=6&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum''


'''Upregulation of HTLV-1 and HTLV-2 expression by HIV-1 in vitro.'''
3. Research on the role of nuclear factor-kappaB-inducing kinase using mice with a specific genotype. The study suggests that the lack of NIK inhibits HTLV replication and interrupts the maintenance of the provirus. ''http://www.ncbi.nlm.nih.gov/pubmed/18312467?ordinalpos=3&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum''
Co-infections with HIV-1 and the human T leukemia virus types 1 and 2 (HTLV-1, HTLV-2) occur frequently, particularly in large metropolitan areas where injection drug use is a shared mode of transmission. Recent evidence suggests that HIV-HTLV co-infections are associated with upregulated HTLV-1/2 virus expression and disease. An in vitro model of HIV-1 and HTLV-1/2 co-infection was utilized to determine if cell free HIV-1 virions or recombinant HIV-1 Tat protein (200-1,000 ng/ml) upregulated HTLV-1/2 expression and infectivity. Exposure to HIV-1 increased the number of HTLV-1 antigen expressing cells, from 6% at baseline to 12% at 24 hr, and 20% at 120 hr (P < 0.05) post-exposure. A similar, although less robust response was observed in HTLV-2 infected cells. HIV-1 co-localized almost exclusively with HTLV-1/2 positive cells. Exposure to HIV-1 Tat protein (1,000 ng/ml) increased HTLV-1 p19 expression almost twofold by 48 hr, and cells co-stimulated with 10 nM phorbol myristate acetate (PMA) showed almost a fourfold increase over baseline. It is concluded that HIV-1 augments HTLV-1/2 infectivity in vitro. The findings also suggest a role for the HIV-1 Tat protein and PMA-inducible cellular factors, in HIV-1 induced HTLV-1/2 antigen expression. ''http://www.ncbi.nlm.nih.gov/pubmed/18205225?ordinalpos=8&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum''


==References==
==References==
1.  http://en.wikipedia.org/wiki/Human_T-lymphotropic_virus


2.  http://www.medicalnewstoday.com/articles/95706.php
2.  http://www.medicalnewstoday.com/articles/95706.php
Line 71: Line 42:
4.  http://www.emedicine.com/med/topic1038.htm
4.  http://www.emedicine.com/med/topic1038.htm


[http://en.citizendium.org/wiki/Main_Page | Citizendium]
5.  http://www.nyborglab.com/research.htm[[Category:Suggestion Bot Tag]]

Latest revision as of 16:01, 29 August 2024

This article is developing and not approved.
 Main Article
 Discussion
Related Articles  [?]
Bibliography  [?]
External Links  [?]
Citable Version  [?]
 
https://en.citizendium.org/wiki/index.php?title=Human_T-lymphotropic_virus&printable=yes
This editable Main Article is under development and subject to a disclaimer.
Human T-lymphotropic virus
HTLV-1 1.jpg
Virus classification
Group: Group VI (ssRNA-RT)
Family: Retroviridae
Genus: Deltaretrovirus
Sero complex: Human T-lymphotropic virus

Human T-lymphotropic virus was first discovered in Japan in 1977 as the first human retrovirus to be identified as such. It is thought to be the disease-causing agent in several ailments. Paraparesis is one disease thought to be caused by the virus where an individual's lower extremities are impaired. The virus is also thought to be an oncovirus, a cancer causing viral agent. Leukemia, a cancer of bone marrow or blood cells, has been linked to T-lymphotropic virus.

Genome structure

The virus' genome consists of a single strand of RNA and uses reverse transcription to form DNA from an RNA template. Among retroviruses HTLV has a unique genome that leads to its unusual pathogenesis. It shares with other viruses the gag-pol-env motif with flanking LTR (long terminal repeat) sequences. It, however, includes a fourth sequence which acts in an ORF(open reading frame), and leads to products that are most likely pathogenic: Tax, Rex, p12, p13, and p30.

Cell structure and metabolism

HTLV is an enveloped virus. A core contains the genetic material as well as reverse transcribing proteins that facilitate transcription from RNA to DNA. This core is encased in a protein shell called a capsid. The outer most portion of the virus is the envelope - a phospholipid bilayer derived from the host cell that helps the virus invade a host cell. Between the envelope and the capsid is a collection of proteins called the tegument.

Ecology

HTLV interacts primarily with human hosts. Close relatives of the virus, however, do exist and invade other animal hosts.

Pathology

The virus, once in the host, can cause a variety of disease. These diseases include HTLV-1 associated myelopathy, opportunistic infections from other microbes due to a debilitated immune system, and cancer. In respect to debilitating the immune system, a unique feedback process involving Tax and Rex, an early and rapid replication of the virus is attained. This is followed by a sudden halt to viral replication. The quick replication and abrupt stop sequence allows for the virus to avoid host defenses. This places HTLV in the unique category of delta retroviruses, whose only other members are a few nonhuman viruses: BLV, STLV (simian T-cell leukemia virus), and PTLV (primate T-cell leukemia virus).

Application to Biotechnology

Current Research

1. Project by The Nyborg Lab of Colorado State University is underway to explore the transciptional regulation of T-cells infected with HTLV. The goal is to study the interactions between the viral proteins, such as the Tax protein, and cellular machinery in vivo and in vitro. http://www.nyborglab.com/research.htm


2. Study being conducted at Fukuoka University is exploring alternatives to treating Adult T-Cell Leukemia/Lymphoma. Current usage of chemotherapy have insufficient results, but application of stem cell technology has yielded a possible new approach to treating the disease. http://www.ncbi.nlm.nih.gov/pubmed/18081707?ordinalpos=6&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum

3. Research on the role of nuclear factor-kappaB-inducing kinase using mice with a specific genotype. The study suggests that the lack of NIK inhibits HTLV replication and interrupts the maintenance of the provirus. http://www.ncbi.nlm.nih.gov/pubmed/18312467?ordinalpos=3&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum

References

2. http://www.medicalnewstoday.com/articles/95706.php

3. http://www.ncbi.nlm.nih.gov/pubmed/

4. http://www.emedicine.com/med/topic1038.htm

5. http://www.nyborglab.com/research.htm

Retrieved from "https://citizendium.org/wiki/index.php?title=Human_T-lymphotropic_virus&oldid=975306"